Management of hematological patients requiring emergency chemotherapy in the intensive care unit
- PMID: 38748265
- PMCID: PMC11164740
- DOI: 10.1007/s00134-024-07454-z
Management of hematological patients requiring emergency chemotherapy in the intensive care unit
Erratum in
-
Correction: Management of hematological patients requiring emergency chemotherapy in the intensive care unit.Intensive Care Med. 2024 Jul;50(7):1208-1209. doi: 10.1007/s00134-024-07494-5. Intensive Care Med. 2024. PMID: 38829534 Free PMC article. No abstract available.
Abstract
Hematological malignancies may require rapid-onset treatment because of their short doubling time, notably observed in acute leukemias and specific high-grade lymphomas. Furthermore, in targeted onco-hematological scenarios, chemotherapy is deemed necessary as an emergency measure when facing short-term, life-threatening complications associated with highly chemosensitive hematological malignancies. The risks inherent in the disease itself, or in the initiation of treatment, may then require admission to the intensive care unit (ICU) to optimize monitoring and initial management protocols. Hyperleukocytosis and leukostasis in acute leukemias, tumor lysis syndrome, and disseminated intravascular coagulation are the most frequent onco-hematological complications requiring the implementation of emergency chemotherapy in the ICU. Chemotherapy must also be started urgently in secondary hemophagocytic lymphohistiocytosis. Tumor-induced microangiopathic hemolytic anemia and plasma hyperviscosity due to malignant monoclonal gammopathy represent infrequent yet substantial indications for emergency chemotherapy. In all cases, the administration of emergency chemotherapy in the ICU requires close collaboration between intensivists and hematology specialists. In this review, we provide valuable insights that aid in the identification and treatment of patients requiring emergency chemotherapy in the ICU, offering diagnostic tools and guidance for their overall initial management.
Keywords: Acute leukemia; Chemotherapy; Emergency; ICU; Lymphoma.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing financial interests.
Figures

References
-
- Wohlfarth P, Staudinger T, Sperr WR, Bojic A, Robak O, Hermann A, Laczika K, Carlstrom A, Riss K, Rabitsch W, Bojic M, Knoebl P, Locker GJ, Obiditsch M, Fuhrmann V, Schellongowski P, Arbeitsgruppe fur hamato-onkologische Intensivmedizin der Osterreichischen Gesellschaft fur Internistische und Allgemeine Intensivmedizin und N Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol. 2014;93:1629–1636. - PubMed
-
- Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Noens LA, Janssens AM, Decruyenaere JM. Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med. 2006;32:93–99. - PubMed
-
- Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, Kang WK, Park K, Jeon K. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. 2011;19:491–495. - PubMed
-
- Moors I, Pene F, Lengline E, Benoit D. Urgent chemotherapy in hematological patients in the ICU. Curr Opin Crit Care. 2015;21:559–568. - PubMed
-
- Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, Nollet J, Steel E, Noens LA, Decruyenaere JM. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med. 2008;34:847–855. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources